Amid a backdrop of trade policy uncertainties and fluctuating market indices, the U.S. stock market remains near record highs, reflecting a complex mix of investor sentiment. In this setting, penny stocks—often associated with smaller or emerging companies—still present intriguing opportunities for those seeking growth potential. These stocks can offer significant returns when supported by strong financial fundamentals, and we’ll explore three examples that stand out for their balance sheet strength and promise for long-term success.

Name

Share Price

Market Cap

Financial Health Rating

Waterdrop (WDH)

$1.41

$509.94M

★★★★★★

WM Technology (MAPS)

$1.01

$169.86M

★★★★★★

Perfect (PERF)

$2.24

$228.14M

★★★★★★

Tuniu (TOUR)

$0.9326

$100.41M

★★★★★★

Safe Bulkers (SB)

$4.11

$420.49M

★★★★☆☆

Cardno (COLD.F)

$0.1701

$6.64M

★★★★★★

BAB (BABB)

$0.84765

$6.16M

★★★★★☆

Lifetime Brands (LCUT)

$4.88

$109.38M

★★★★★☆

North European Oil Royalty Trust (NRT)

$4.84

$44.48M

★★★★★★

Tandy Leather Factory (TLF)

$3.296

$28.06M

★★★★★★

Click here to see the full list of 421 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment in the United States with a market cap of $101.58 million.

Operations: The company generates revenue of $154.05 million from its segment focused on the development and commercialization of monoclonal antibody-based therapeutics.

Market Cap: $101.58M

MacroGenics, Inc., with a market cap of US$101.58 million, is navigating challenges typical for clinical-stage biopharmaceutical companies. Despite generating US$154.05 million in revenue from monoclonal antibody therapeutics, the company remains unprofitable and was recently removed from multiple Russell indices. However, it secured a US$70 million upfront payment through a royalty purchase agreement with Sagard for ZYNYZ sales rights, bolstering its cash position to support operations until mid-2027. Management’s seasoned experience and strategic cost-reduction initiatives may help stabilize its financial footing amidst high share price volatility and declining earnings forecasts over the next three years.

Story Continues